Business Wire

Yokogawa Establishes Sustainability Goals for the Year 2050

Del

Yokogawa Electric Corporation (TOKYO:6841) announces that it has developed sustainability goals for the year 2050 that will guide its efforts to make the world a better place for future generations.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170806005002/en/

Yokogawa's sustainability goals: "Three goals" (Graphic: Yokogawa Electric Corporation)

Yokogawa's sustainability goals: "Three goals" (Graphic: Yokogawa Electric Corporation)

Yokogawa’s efforts to achieve a sustainable society are in keeping with the Paris Agreement, which was adopted in 2015 by the 21st Framework Convention on Climate Change (COP21) to provide a basis for global efforts to tackle issues related to climate change. The agreement calls for the achievement of net-zero greenhouse gas emissions by the second half of this century. Also in 2015, the UN adopted the 2030 Agenda for Sustainable Development centering on the Sustainable Development Goals (SDGs). Through these initiatives, a global consensus is developing on how to address these issues, and the direction that companies should take is becoming clear.

Yokogawa’s efforts to achieve sustainability and build a brighter future for all are based on the company’s corporate philosophy, which states: “As a company, our goal is to contribute to society through broad-ranging activities in the areas of measurement, control, and information. Individually, we aim to combine good citizenship with the courage to innovate.” To ensure a flexible response to environmental and technology changes and guide its long-term efforts to address social issues, Yokogawa is committing itself to the achievement of goals that are based on a vision of where our society should be by the year 2050. Through the selection of products and solutions and the formulation of medium-term business plans and the like that are based on environmental, economic, and societal considerations, Yokogawa will carry out the detailed tasks needed to achieve these goals.

Commenting on this initiative, Takashi Nishijima, Yokogawa President and CEO, says: “Companies have a growing responsibility to respond to issues such as population growth and the rising use of fossil fuels that are addressed in the Paris Agreement and the SDGs. Yokogawa provides solutions that improve the stability, efficiency, and safety of operations at industrial plants and other infrastructure facilities by, for example, speeding up processes, reducing workloads, and saving energy. Yokogawa needs to work harder to broaden its solutions so that it can address other issues that impact our society. Yokogawa will establish key performance indicators (KPIs) to evaluate on a medium-term basis the achievement of its sustainability goals, and will continue to create new value through co-innovation with its customers and partners.

Statement on Yokogawa’s aspiration for sustainability

Yokogawa will work to achieve net-zero emissions, make a transition to a circular economy, and ensure the well-being of all by 2050, thus making the world a better place for future generations.

We will undergo the necessary transformation to achieve these goals by 1. becoming more adaptable and resilient, 2. evolving our businesses to engage in regenerative value creation, and 3. promoting co-innovation with our stakeholders.

 

Yokogawa’s sustainability goals: “Three goals”

Environmental:      

Achieve net-zero emissions

Economic:

Make transition to circular economy

Social:

Ensure well-being

 

Achieve net-zero emissions; stopping climate change
Climate change is an urgent issue that requires a global response. We aim for net-zero emissions, which means that the greenhouse gas concentrations in the atmosphere do not rise due to the balance of emissions and the absorption of greenhouse gases, which can be accomplished through the introduction of renewable energy and efficient use of energy. We are also working to reduce the impact of natural disasters and respond to biodiversity issues.

Make the transition to a circular economy; circulation of resources and efficiency
The transformation from a one-way economy based on the take, make, and dispose model to an economy where resources are circulated without waste, and the transition to businesses that emphasize services, are under way. We aim to realize a social framework and ecosystem in which various resources are circulated without waste and assets are utilized effectively. We also are contributing to the efficient use of water resources and the supply of safe drinking water.

Ensure well-being; quality life for all
With the aim of achieving the physical, mental, and social well-being described in the 2030 Agenda for Sustainable Development adopted by the United Nations in 2015, we support people's health and prosperity through the achievement of safe and comfortable workplaces and our pursuits in such areas as the life sciences and drug discovery. We promote human resource development and employment creation in local communities, and diversity and inclusion.

Yokogawa sustainability policies: www.yokogawa.com/csr/policy

About Yokogawa
Yokogawa's global network of 113 companies spans 60 countries. Founded in 1915, the US$3.5 billion company engages in cutting-edge research and innovation. Yokogawa is active in the industrial automation and control (IA), test and measurement, and aviation and other businesses segments. The IA segment plays a vital role in a wide range of industries including oil, chemicals, natural gas, power, iron and steel, pulp and paper, pharmaceuticals, and food. Targeting this segment, Yokogawa helps companies maximize their profits by offering a wide range of highly reliable products and working with the subsidiary KBC Advanced Technologies to provide premium solutions and services. For more information about Yokogawa, please visit www.yokogawa.com.

Contact information

Yokogawa Electric Corporation
Public Relations, Integrated Communications Center
Yokogawa-pr@cs.jp.yokogawa.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom